Scholarlink

<p>The treatment of cancer is constantly changing due to immunotherapies, targeted medicines, and personalized medicine. Advances in cell-free DNA (cfDNA) and other biomarkers are making it possible for earlier detection, real-time monitoring, and more accurate treatment. Standardization, fair access, and strong trial evidence are necessary for clinical integration. Immunotherapies take advantage of the high specificity of the immune system’s constituents, especially antibodies and modified immune cells, to be employed for both diagnosis and prognosis. Immunotherapies use biomarkers to diagnose diseases and aid in prognostication by predicting how a patient will react to treatment and how their illness will progress. A promising diagnostic technique for timely diagnosis of cancer and surveillance is cfDNA. This publication provides an overview of the vital function circulating cell-free DNA plays in cancer treatment and early diagnosis. The most recent advancements in cfDNA-based immunotherapy research are covered, along with cfDNA detection techniques and its possible use as a diagnostic biomarker. According to the research, cfDNA is essential for early cancer detection and customized cancer treatment, and it has significant potential to enhance patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Development and Application of Immunotherapies, Targeted Therapies, Personalized Medicine and Advancements in Biomarkers for Diagnosis and Prognosis, Such as Cell-Free DNA Tests

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Anita Imoseme Alofoje,
  • Great Iruoghene Edo,
  • Morenike Olufunmilayo Akpo,
  • Patrick Othuke Akpoghelie,
  • Agatha Ngukuran Jikah,
  • Emad Yousif,
  • Joseph Oghenewogaga Owheruo,
  • Ufuoma Augustina Igbuku,
  • Raghda S. Makia,
  • Arthur Efeoghene Athan Essaghah,
  • Ephraim Evi Alex Oghroro,
  • Huzaifa Umar,
  • Dina S. Ahmed,
  • Ahmed A. Alamiery

摘要

The treatment of cancer is constantly changing due to immunotherapies, targeted medicines, and personalized medicine. Advances in cell-free DNA (cfDNA) and other biomarkers are making it possible for earlier detection, real-time monitoring, and more accurate treatment. Standardization, fair access, and strong trial evidence are necessary for clinical integration. Immunotherapies take advantage of the high specificity of the immune system’s constituents, especially antibodies and modified immune cells, to be employed for both diagnosis and prognosis. Immunotherapies use biomarkers to diagnose diseases and aid in prognostication by predicting how a patient will react to treatment and how their illness will progress. A promising diagnostic technique for timely diagnosis of cancer and surveillance is cfDNA. This publication provides an overview of the vital function circulating cell-free DNA plays in cancer treatment and early diagnosis. The most recent advancements in cfDNA-based immunotherapy research are covered, along with cfDNA detection techniques and its possible use as a diagnostic biomarker. According to the research, cfDNA is essential for early cancer detection and customized cancer treatment, and it has significant potential to enhance patient outcomes.